Genetically modified plants might be used for production of non-native proteins as they have artificially inserted gene(s) or transgene(s) that comes from an unrelated plant or from a different species. Thus, the production of antibodies via these transgenic plants could be achieved in a low cost and scalable option. Though plantibodies have many advantages in the treatment of different pathologic conditions however, the technology is not well known and only practiced in Africa (in general) and in Ethiopia (in particularly in the veterinary sector). The low-cost, high-scalability and safety characteristics of a plant-based production system offer an attractive alternative for commercial pharmaceutical products.